Literature DB >> 22127645

Regulation by survivin of cancer cell death induced by F14512, a polyamine-containing inhibitor of DNA topoisomerase II.

Caroline Ballot1, Manel Jendoubi, Jérome Kluza, Aurélie Jonneaux, William Laine, Pierre Formstecher, Christian Bailly, Philippe Marchetti.   

Abstract

F14512, an epipodophyllotoxin derivative equipped with a spermine moiety, is selectively taken up by the polyamine transport system over-active in tumor cells. F14512 was identified as a selective anticancer agent with a broad spectrum of antitumor activities and is currently undergoing phase I clinical trial in onco-hematology. However, the mechanism by which F14512 exerts its selective effects on neoplastic cells remains poorly understood. In this study, using mainly P388 leukemia cells, we showed that activation of the DNA damage response by F14512 did not induce immediate apoptosis but resulted in an early growth arrest. F14512-induced G2 arrest was accompanied by the appearance of a senescence-like phenotype (characterized by an increased β-galactosidase staining) with up-regulation of the cyclin-dependent kinase inhibitor p16, and cyclin D1. The early senescence-based cell cycle block was characterized by a marked increase of the level of the IAP protein survivin, but not cIAP2, in P388 cells as well as in three other leukemia and melanoma cell types. The Thr(34)-phosphorylated form of survivin was observed within 4 h after F14512 exposure. Inhibition of survivin by siRNA resulted in a switch from senescence-like growth arrest to apoptosis. Compared with the parental drug etoposide, F14512-induced DNA damage signaling pathway resulted in greater senescence like-growth arrest and delayed apoptosis. Collectively, our data show that senescence arrest and subsequent apoptosis are powerful mechanisms mediating the chemotherapeutic effects of F14512 and identify survivin as the molecular determinant responsible for a qualitative shift in cell fate from senescence to apoptosis upon treatment with F14512.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22127645     DOI: 10.1007/s10495-011-0681-2

Source DB:  PubMed          Journal:  Apoptosis        ISSN: 1360-8185            Impact factor:   4.677


  3 in total

1.  Activity of the polyamine-vectorized anti-cancer drug F14512 against pediatric glioma and neuroblastoma cell lines.

Authors:  Pierre Leblond; Elodie Boulet; Christine Bal-Mahieu; Arnaud Pillon; Anna Kruczynski; Nicolas Guilbaud; Christian Bailly; Thierry Sarrazin; Eric Lartigau; Amélie Lansiaux; Samuel Meignan
Journal:  Invest New Drugs       Date:  2014-07-11       Impact factor: 3.850

2.  Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancer.

Authors:  Alexandra Leary; Christophe Le Tourneau; Andrea Varga; Marie-Paule Sablin; Carlos Gomez-Roca; Nicolas Guilbaud; Aurelie Petain; Mariya Pavlyuk; Jean-Pierre Delord
Journal:  Invest New Drugs       Date:  2018-12-14       Impact factor: 3.850

3.  Another facet to the anticancer response to lamellarin D: induction of cellular senescence through inhibition of topoisomerase I and intracellular Ros production.

Authors:  Caroline Ballot; Alain Martoriati; Manel Jendoubi; Sébastien Buche; Pierre Formstecher; Laurent Mortier; Jérome Kluza; Philippe Marchetti
Journal:  Mar Drugs       Date:  2014-01-27       Impact factor: 5.118

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.